Status:
UNKNOWN
Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Conditions:
Non-Muscle Invasive Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. ...
Detailed Description
Bladder cancer is the 6th most common cancer in the United States, affecting more men than women. The usual first treatment for NMIBC (Ta, T1,and CIS) is transurethral resection of the bladder tumors ...
Eligibility Criteria
Inclusion
- Histologically-confirmed non muscle-invasive urothelial carcinoma (transitional cell carcinoma) of the bladder.
- Subjects must have received adequate BCG treatment defined as at least 2 courses of BCG, i.e., at least one induction and one maintenance course or at least 2 induction courses.
- The subject's disease is refractory or has relapsed following adequate BCG treatment.
- Male or non-pregnant, non-breastfeeding female, age 18 years or older at date of consent.
- All women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of the first dose of study therapy.
- All sexually active subjects agree to use barrier contraception (i.e., condoms) while receiving study treatment and for 120 days following their last dose of study treatment.
- Karnofsky performance status ≥ 60.
- Ability to understand and sign an Independent Ethics Committee-or Institutional Review Board-approved informed consent document.
Exclusion
- The subject is pregnant or breastfeeding.
- Evidence of urethral or upper tract transitional cell carcinoma (TCC) within the past 2 years.
- Subjects with hydronephrosis, except for those subjects where hydronephrosis has been longstanding and diagnostic evaluation at Screening shows no evidence of tumor.
- Any intravesicular or other chemotherapy treatment within 2 weeks or any investigational agent within 4 weeks prior to the initial dose of study drug.
- History of recurrent severe urinary tract infections (UTIs) per investigator judgment. Subjects with a current UTI requiring antibiotic treatment may defer the initiation of Vicinium treatment on Day 1 until resolution of the UTI.
- he subject has a diagnosis of another malignancy within 2 years before the first dose of study treatment.
- A QTc interval of \>470 msec by the Fridericia formula (QTcF), at the Screening ECG.
- Subjects who, in the opinion of the Investigator, cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy, biopsy) due to the presence of serious comorbid condition(s).
- Local or severe allergy to any components of the drug regimen.
Key Trial Info
Start Date :
March 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT04859751
Start Date
March 23 2021
End Date
December 1 2023
Last Update
April 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, China